Terms: = Liver cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Prognosis
51 results:
1. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
2. Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis.
Li HY; Zheng LL; Hu N; Wang ZH; Tao CC; Wang YR; Liu Y; Aizimuaji Z; Wang HW; Zheng RQ; Xiao T; Rong WQ
World J Gastroenterol; 2024 Mar; 30(9):1224-1236. PubMed ID: 38577190
[TBL] [Abstract] [Full Text] [Related]
3. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
5. Characterization of integrated hepatitis B virus DNA harboring pre-S mutations in hepatocellular carcinoma patients with ground glass hepatocytes.
Su YP; Lin SY; Su IJ; Kao YL; Shen SC; Earl JP; Ehrlich GD; Chen CY; Huang W; Su YH; Tsai HW
J Med Virol; 2024 Jan; 96(1):e29348. PubMed ID: 38180275
[TBL] [Abstract] [Full Text] [Related]
6. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
Innes H; Morgan MY; Hampe J; Stickel F; Buch S
Aliment Pharmacol Ther; 2023 Sep; 58(6):623-631. PubMed ID: 37470344
[TBL] [Abstract] [Full Text] [Related]
7. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
[TBL] [Abstract] [Full Text] [Related]
8. [Differential diagnostic between hepatocellular carcinoma and hepatoid carcinoma with bone metastasis revelation: What tools can be used?].
Neyrand S; Bringuier PP; Benzerdjeb N; Hervieu V; Fenouil T
Ann Pathol; 2023 Sep; 43(5):407-411. PubMed ID: 36822899
[TBL] [Abstract] [Full Text] [Related]
9. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.
Yang Z; Liu J; Xue F; Zhang L; Xue H; Wu Y; Bai S; Du F; Wang X; Deng W; Song C; Wang K
Ann Hepatol; 2023; 28(2):100898. PubMed ID: 36634747
[TBL] [Abstract] [Full Text] [Related]
10. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.
Pallerla SR; Hoan NX; Rachakonda S; Meyer CG; Van Tong H; Toan NL; Linh LTK; Giang DP; Kremsner PG; Bang MH; Song LH; Velavan TP
BMC Med Genomics; 2022 Nov; 15(1):235. PubMed ID: 36345011
[TBL] [Abstract] [Full Text] [Related]
11. Near complete response to a pembrolizumab-based therapeutic strategy in an abdominal metastatic head and neck squamous cell carcinoma case.
Wu T; Liang F; Lin P; Li Y; Huang X; Han P
Hum Vaccin Immunother; 2022 Nov; 18(6):2093075. PubMed ID: 35878084
[TBL] [Abstract] [Full Text] [Related]
12. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract] [Full Text] [Related]
13. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.
Kim HI; Lim J; Shim JH
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2069-2077. PubMed ID: 34459972
[TBL] [Abstract] [Full Text] [Related]
14. Nano-Gold PCR in Detection of
Zhao J; Li L; Guo L; Wang R; Zhao Y; Li W; Liu Y; Ma Y; Jia J
J Biomed Nanotechnol; 2021 Jul; 17(7):1284-1292. PubMed ID: 34446132
[TBL] [Abstract] [Full Text] [Related]
15. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract] [Full Text] [Related]
16. Hepatocellular Carcinomas: Towards a pathomolecular approach.
Paradis V
Liver Int; 2021 Jun; 41 Suppl 1():83-88. PubMed ID: 34155797
[TBL] [Abstract] [Full Text] [Related]
17. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
Nakatsuka T; Nakagawa H; Hayata Y; Wake T; Yamada T; Nishibatake Kinoshita M; Nakagomi R; Sato M; Minami T; Uchino K; Enooku K; Kudo Y; Tanaka Y; Kishikawa T; Otsuka M; Tateishi R; Koike K
J Gastroenterol; 2021 May; 56(5):456-469. PubMed ID: 33712873
[TBL] [Abstract] [Full Text] [Related]
18. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
Péneau C; Imbeaud S; La Bella T; Hirsch TZ; Caruso S; Calderaro J; Paradis V; Blanc JF; Letouzé E; Nault JC; Amaddeo G; Zucman-Rossi J
Gut; 2022 Mar; 71(3):616-626. PubMed ID: 33563643
[TBL] [Abstract] [Full Text] [Related]
19. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract] [Full Text] [Related]
20. Targeting the NCOA3-SP1-tert axis for tumor growth in hepatocellular carcinoma.
Li W; Yan Y; Zheng Z; Zhu Q; Long Q; Sui S; Luo M; Chen M; Li Y; Hua Y; Deng W; Lai R; Li L
Cell Death Dis; 2020 Nov; 11(11):1011. PubMed ID: 33239622
[TBL] [Abstract] [Full Text] [Related]
[Next]
